Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) [Yahoo! Finance]
Cyclo Therapeutics, Inc. (CYTH)
Company Research
Source: Yahoo! Finance
Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for NPC1 Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025 Trappsol ® Cyclo™ demonstrated to be well tolerated in ongoing substudy with a safety profile consistent with that of completed phases GAINESVILLE, Fla., September 05, 2024 BUSINESS WIRE Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the presentation of positive preliminary data from its ongoing pivotal Phase 3 study ("TransportNPC™") and substudy evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1). The data were presented in two poster presentations at the S
Show less
Read more
Impact Snapshot
Event Time:
CYTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTH alerts
High impacting Cyclo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CYTH
News
- Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARCH, CYTH, VGR on Behalf of ShareholdersPR Newswire
- Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)Business Wire
- Cyclo Therapeutics, Inc. (NASDAQ: CYTH) had its "hold" rating re-affirmed by analysts at Maxim Group.MarketBeat
CYTH
Sec Filings
- 11/18/24 - Form 4
- 11/18/24 - Form 4
- 11/18/24 - Form 4
- CYTH's page on the SEC website